阿尔茨海默病中的炎症：与发病机制和治疗的相关性。
Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy.
机构信息
Division of Clinical Neurosciences, School of Medicine, University of Southampton, Mailpoint 806, Level D, South Pathology Block, Southampton General Hospital, Southampton, SO16 6YD, UK.
出版信息
Alzheimers Res Ther. 2010 Jan 22;2(1):1. doi: 10.1186/alzrt24.
Abstract
Evidence for the involvement of inflammatory processes in the pathogenesis of Alzheimer's disease (AD) has been documented for a long time. However, the inflammation hypothesis in relation to AD pathology has emerged relatively recently. Even in this hypothesis, the inflammatory reaction is still considered to be a downstream effect of the accumulated proteins (amyloid beta (Abeta) and tau). This review aims to highlight the importance of the immune processes involved in AD pathogenesis based on the outcomes of the two major inflammation-relevant treatment strategies against AD developed and tested to date in animal studies and human clinical trials - the use of anti-inflammatory drugs and immunisation against Abeta.
摘要
很长一段时间以来，人们已经发现炎症过程参与了阿尔茨海默病（AD）的发病机制。然而，与 AD 病理学相关的炎症假说直到最近才出现。即使在这个假说中，炎症反应仍然被认为是积累的蛋白质（β淀粉样蛋白（Abeta）和 tau）的下游效应。本综述旨在根据迄今为止在动物研究和人类临床试验中针对 AD 开发和测试的两种主要与炎症相关的治疗策略的结果，强调参与 AD 发病机制的免疫过程的重要性——使用抗炎药物和针对 Abeta 的免疫接种。
相似文献
1
Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy.阿尔茨海默病中的炎症：与发病机制和治疗的相关性。
Alzheimers Res Ther. 2010 Jan 22;2(1):1. doi: 10.1186/alzrt24.
2
Alzheimer's Disease is Driven by Intraneuronally Retained Beta-Amyloid Produced in the AD-Specific, βAPP-Independent Pathway: Current Perspective and Experimental Models for Tomorrow.阿尔茨海默病由在AD特异性、β-淀粉样前体蛋白（βAPP）非依赖途径中产生并在神经元内保留的β-淀粉样蛋白驱动：当前观点及未来实验模型
Ann Integr Mol Med. 2020;2(1):90-114. doi: 10.33597/aimm.02-1007.
3
Alzheimer's Is a Multiform Disease of Sustained Neuronal Integrated Stress Response Driven by the C99 Fragment Generated Independently of AβPP; Proteolytic Production of Aβ Is Suppressed in AD-Affected Neurons: Evolution of a Theory.阿尔茨海默病是一种由独立于淀粉样前体蛋白（AβPP）产生的C99片段驱动的持续性神经元综合应激反应的多形性疾病；在受阿尔茨海默病影响的神经元中，Aβ的蛋白水解产生受到抑制：一种理论的演变
Int J Mol Sci. 2025 Apr 29;26(9):4252. doi: 10.3390/ijms26094252.
4
Precursor-Independent Overproduction of Beta-Amyloid in AD: Mitochondrial Dysfunction as Possible Initiator of Asymmetric RNA-Dependent βAPP mRNA Amplification. An Engine that Drives Alzheimer's Disease.阿尔茨海默病中β-淀粉样蛋白的前体非依赖性过量产生：线粒体功能障碍作为不对称RNA依赖性β-淀粉样前体蛋白（βAPP）mRNA扩增的可能引发因素。一种驱动阿尔茨海默病的机制
Ann Integr Mol Med. 2019;1(1):61-74. Epub 2019 Nov 20.
5
Alzheimer's disease.阿尔茨海默病
Subcell Biochem. 2012;65:329-52. doi: 10.1007/978-94-007-5416-4_14.
6
The antimicrobial protection hypothesis of Alzheimer's disease.阿尔茨海默病的抗菌保护假说。
Alzheimers Dement. 2018 Dec;14(12):1602-1614. doi: 10.1016/j.jalz.2018.06.3040. Epub 2018 Oct 9.
7
Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.阿尔茨海默病的免疫疗法：从抗β-淀粉样蛋白到基于tau 的免疫接种策略。
Immunotherapy. 2012 Feb;4(2):213-38. doi: 10.2217/imt.11.170.
8
Peripheral blood amyloid-β involved in the pathogenesis of Alzheimer's disease via impacting on peripheral innate immune cells.外周血淀粉样-β通过影响外周固有免疫细胞参与阿尔茨海默病的发病机制。
J Neuroinflammation. 2024 Jan 4;21(1):5. doi: 10.1186/s12974-023-03003-5.
9
Examining the potential clinical value of curcumin in the prevention and diagnosis of Alzheimer's disease.研究姜黄素在阿尔茨海默病预防和诊断中的潜在临床价值。
Br J Nutr. 2016 Feb 14;115(3):449-65. doi: 10.1017/S0007114515004687. Epub 2015 Dec 14.
10
ACH2.0/E, the Consolidated Theory of Conventional and Unconventional Alzheimer's Disease: Origins, Progression, and Therapeutic Strategies.ACH2.0/E，即传统和非传统阿尔茨海默病的综合理论：起源、进展和治疗策略。
Int J Mol Sci. 2024 May 30;25(11):6036. doi: 10.3390/ijms25116036.
引用本文的文献
1
Murine Non-Transgenic Models of Alzheimer's Disease Pathology: Focus on Risk Factors.阿尔茨海默病病理学的小鼠非转基因模型：关注风险因素。
Brain Sci. 2025 Mar 19;15(3):322. doi: 10.3390/brainsci15030322.
2
Network Diffusion-Constrained Variational Generative Models for Investigating the Molecular Dynamics of Brain Connectomes Under Neurodegeneration.用于研究神经退行性变下脑连接组分子动力学的网络扩散约束变分生成模型
Int J Mol Sci. 2025 Jan 26;26(3):1062. doi: 10.3390/ijms26031062.
3
Physiopathological mechanisms underlying Alzheimer's disease: a narrative review.阿尔茨海默病的病理生理机制：一篇叙述性综述。
Dement Neuropsychol. 2024 Dec 16;18:e2024VR01. doi: 10.1590/1980-5764-DN-2024-VR01. eCollection 2024.
4
APOE genotype and brain amyloid are associated with changes in the plasma proteome in elderly subjects without dementia.APOE基因分型和脑淀粉样蛋白与无痴呆症老年受试者血浆蛋白质组的变化有关。
Ann Clin Transl Neurol. 2025 Feb;12(2):366-382. doi: 10.1002/acn3.52250. Epub 2024 Dec 17.
5
Light-based gamma entrainment with novel invisible spectral flicker stimuli.基于新型不可见光谱闪烁刺激的光基伽马同步
Sci Rep. 2024 Nov 29;14(1):29747. doi: 10.1038/s41598-024-75448-4.
6
Added value of inflammatory plasma biomarkers to pathologic biomarkers in predicting preclinical Alzheimer's disease.炎性血浆生物标志物对预测临床前阿尔茨海默病的病理生物标志物的附加值。
J Alzheimers Dis. 2024 Nov;102(1):89-98. doi: 10.1177/13872877241283692. Epub 2024 Oct 3.
7
Prostaglandins in the Inflamed Central Nervous System: Potential Therapeutic Targets.炎症性中枢神经系统中的前列腺素：潜在的治疗靶点。
Curr Drug Targets. 2024;25(13):885-908. doi: 10.2174/0113894501323980240815113851.
8
Causal relationship between Alzheimer's disease and unstable angina: a bidirectional Mendelian randomization analysis.阿尔茨海默病与不稳定型心绞痛之间的因果关系：一项双向孟德尔随机化分析
Front Psychiatry. 2024 Jul 9;15:1435394. doi: 10.3389/fpsyt.2024.1435394. eCollection 2024.
9
From Gut Microbiota to Brain Waves: The Potential of the Microbiome and EEG as Biomarkers for Cognitive Impairment.从肠道微生物群到脑电波：微生物组和 EEG 作为认知障碍生物标志物的潜力。
Int J Mol Sci. 2024 Jun 18;25(12):6678. doi: 10.3390/ijms25126678.
10
Transcriptome Study of rd1Mouse Brain and Association with Parkinson's Disease.rd1小鼠大脑的转录组研究及其与帕金森病的关联
ACS Omega. 2024 Jun 6;9(24):25756-25765. doi: 10.1021/acsomega.3c09938. eCollection 2024 Jun 18.
本文引用的文献
1
Accumulation of tau induced in neurites by microglial proinflammatory mediators.小胶质细胞促炎介质诱导神经突中tau蛋白的积累。
FASEB J. 2009 Aug;23(8):2502-13. doi: 10.1096/fj.08-123877. Epub 2009 Mar 16.
2
Antibody response and plasma Abeta1-40 levels in young Microcebus murinus primates immunized with Abeta1-42 and its derivatives.用β淀粉样蛋白1-42及其衍生物免疫的幼年倭狐猴灵长类动物的抗体反应和血浆β淀粉样蛋白1-40水平。
Vaccine. 2009 Feb 11;27(7):957-64. doi: 10.1016/j.vaccine.2008.12.012. Epub 2008 Dec 27.
3
Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies.针对阿尔茨海默病及相关tau蛋白病中病理性tau蛋白的免疫疗法。
J Alzheimers Dis. 2008 Oct;15(2):157-68. doi: 10.3233/jad-2008-15202.
4
Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIB-PET study.阿尔茨海默病中的小胶质细胞、淀粉样蛋白与认知：一项[11C]（R）PK11195-PET和[11C]PIB-PET研究。
Neurobiol Dis. 2008 Dec;32(3):412-9. doi: 10.1016/j.nbd.2008.08.001. Epub 2008 Aug 15.
5
Amyloid-beta immunisation for Alzheimer's disease.用于阿尔茨海默病的β淀粉样蛋白免疫疗法。
Lancet Neurol. 2008 Sep;7(9):805-11. doi: 10.1016/S1474-4422(08)70170-4. Epub 2008 Jul 28.
6
Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial.β淀粉样蛋白42免疫治疗对阿尔茨海默病的长期影响：一项随机、安慰剂对照的I期试验随访
Lancet. 2008 Jul 19;372(9634):216-23. doi: 10.1016/S0140-6736(08)61075-2.
7
CNI-1493 inhibits Abeta production, plaque formation, and cognitive deterioration in an animal model of Alzheimer's disease.CNI-1493可抑制阿尔茨海默病动物模型中的β淀粉样蛋白生成、斑块形成以及认知功能衰退。
J Exp Med. 2008 Jul 7;205(7):1593-9. doi: 10.1084/jem.20060467. Epub 2008 Jun 23.
8
Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology.阻断TGF-β-Smad2/3先天免疫信号可减轻阿尔茨海默病样病理。
Nat Med. 2008 Jun;14(6):681-7. doi: 10.1038/nm1781. Epub 2008 Jun 1.
9
Toll-like receptor 2 acts as a natural innate immune receptor to clear amyloid beta 1-42 and delay the cognitive decline in a mouse model of Alzheimer's disease.Toll样受体2作为一种天然的固有免疫受体，可清除β淀粉样蛋白1-42，并延缓阿尔茨海默病小鼠模型中的认知衰退。
J Neurosci. 2008 May 28;28(22):5784-93. doi: 10.1523/JNEUROSCI.1146-08.2008.
10
Toll-like receptors in defense and damage of the central nervous system.Toll样受体在中枢神经系统防御与损伤中的作用
J Neuroimmune Pharmacol. 2007 Dec;2(4):297-312. doi: 10.1007/s11481-007-9071-5. Epub 2007 Apr 3.
Zotero 插件